Study on the effect and safety of intravenous calcium supplementation on sarcopenia

Efficacy and safety of intravenous calcium supplementation in the treatment of sarcopenia - Calcium supplement in the treatment of sarcopenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069441

Enrollment

Unknown

Registered

2023-03-16

Start date

2023-03-24

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

intravenous calcium groups:intravenous calcium

Control group:normal saline

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for sarcopenia; 2. Agree to participate in this study; 3. Have not taken any hormone drugs and other drugs that affect the study for at least 3 months before enrollment; 4. Underlying diseases stable, does not affect treatment and observation; 5. Aged >= 60 years; 6. Agreed and approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1. Intellectual, mental, cognitive dysfunction or other neurological dysfunction; 2. Patients with hypercalcemia; 3. Heart failure.

Design outcomes

Primary

Measure	Time frame
skeletal muscle index, SMI;Muscle strength measurement;Measurement of muscle function;	—

Secondary

Measure	Time frame
Cross-sectional area of psoas major;adverse event;Vital signs;Local injection site reaction;	—

Countries

China

Contacts

Public ContactShengkai Ye

The 967th Hospital of P.L.A

yeshengkai@163.com+86 411 80841197

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026